Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why 10x Genomics Stock Is Sinking Today


Shares of 10x Genomics (NASDAQ: TXG) have sunk 13.9% as of 10:56 a.m. ET on Thursday. The big decline came after the life sciences company announced its 2021 fourth-quarter and full-year results following market close on Wednesday.

10x Genomics reported fourth-quarter revenue of $490.5 million, a 64% year-over-year increase. It posted a net loss in the quarter of $18.4 million, or $0.16 per share. Although the company's bottom line reflected improvement compared to the prior-year period, it didn't meet the consensus Wall Street estimate of a net loss of $0.09 per share.

Investors were most disappointed by 10x's guidance for full-year 2022. The company stated that it expects revenue this year will be between $600 million and $630 million. The midpoint of that range represents 24% year-over-year growth. However, it fell short of the average analysts' revenue projection of $679.9 million.

Continue reading


Source Fool.com

Like: 0
TXG
Teilen

Kommentare